Management of children with sickle cell disease: A comprehensive review of the literature

Pediatrics

Volumn 128, Issue 6, 2011, Pages

  Kavanagh, Patricia L ^a   Sprinz, Philippa G ^a   Vinci, Samuel R ^a   Bauchner, Howard ^b   Wang, C Jason ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMERICAN MEDICAL ASSOCIATION   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Child and adolescent; Evidence based medicine; Sickle cell disease; Systematic reviews

Indexed keywords

ACETYLSALICYLIC ACID; ANTISICKLING AGENT; DEFERASIROX; DEFEROXAMINE; DEXAMETHASONE; FOLIC ACID; HYDROXYUREA; KETOROLAC; MORPHINE; NIPRISAN; NITRIC OXIDE; PENICILLIN DERIVATIVE; PIROXICAM; PLACEBO; PNEUMOCOCCUS VACCINE; POLOXAMER; PROPIONYLCARNITINE; TINZAPARIN; UNCLASSIFIED DRUG; ZINC;

ACUTE CHEST SYNDROME; APLASTIC CRISIS; ARTICLE; CHILD; CHILD CARE; CHILD HEALTH; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; DOPPLER ECHOGRAPHY; DRUG DOSAGE FORM COMPARISON; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FEVER; GENETIC COUNSELING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON OVERLOAD; LEG ULCER; LUNG FUNCTION TEST; META ANALYSIS (TOPIC); NEWBORN SCREENING; OSTEOMYELITIS; PAIN; PATIENT CARE; PRIAPISM; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIA; STROKE; UNITED STATES; VITAMIN SUPPLEMENTATION; WELLBEING;

ANEMIA, SICKLE CELL; CHILD; HUMANS;

EID: 83155176170     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-3686     Document Type: Article

References (66)

1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(suppl 4):S512-S521
2. National Heart Lung and Blood Institute. The Management of Sickle Cell Disease. Bethesda, MD: National Institutes of Health; 2002. NIH publication No. 02-2117
3. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340(13):1021-1030
4. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative study of sickle cell disease. Blood. 1995;86(2):776-783
5. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314(25):1593-1599
6. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121(3):562-569
7. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr. 2003;143(4):438-444
8. Yanni E, Grosse SD, Yang Q, et al. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr. 2009;154(4):541-545
9. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447-3452
10. Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia Trial I. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769-2778
11. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med. 1998;339(1):5-11
12. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching"agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996;75(6):300-326
13. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354-2363
14. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6):1960-1964
15. Section on Hematology/Oncology and Committee on Genetics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109(3):526-535
16. Dick MC. Standards for the management of sickle cell disease in children. Arch Dis Child Ed Pract. 2008;93(6):169-176
17. US Preventive Services Task Force. Procedure Manual. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Publication No. 08-05118-EF. Available at: www. uspreventiveservicestaskforce.org/ uspstf08/methods/ procmanual4.htm. Accessed July 5, 2010
18. Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase a2. Br J Haematol. 2007;136(2):343-344
19. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 1998;92(9):3082-3089
20. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2):392-396
21. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assess of inhaled nitric oxide for acute vasoocclusive crisis in pediatric patients with sickle cell disease [published correction appears in JAMA. 2004;292(8):925]. JAMA. 2003;289(9):1136-1142
22. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286(17):2099-2106
23. Adams-Graves P, Kedar A, Koshy M, et al. Rheothrx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood. 1997;90(5):2041-2046
24. Hardwick WE, Jr, Givens TG, Monroe KW, King WD, Lawley D. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999;15(3):179-182
25. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997;350(9088):1358-1361
26. Kopecky EA, Jacobson S, Joshi P, Koren G. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther. 2004;75(3):140-146
27. Eke FU, Obamyonyi A, Eke NN, Oyewo EA. An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis. Trop Med Int Health. 2000;5(2):81-84
28. Lemanek KL, Ranalli M, Lukens C. A randomized controlled trial of massage therapy in children with sickle cell disease. J Pediatr Psychol. 2009;34(10):1091-1096
29. Alvim RC, Viana MB, Pires MAS, et al. Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. Acta Haematol. 2005;113(4):228-233
30. Wambebe C, Khamofu H, Momoh JA, et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of niprisan in patients with sickle cell disorder. Phytomedicine. 2001;8(4):252-261
31. Serjeant BE, Harris J, Thomas P, Serjeant GR. Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study. J Am Acad Dermatol. 1997;37(3 pt 1):491-493
32. Chernoff RG, Ireys HT, DeVet KA, Kim YJ. A randomized, controlled trial of a community-based support program for families of children with chronic illness: pediatric outcomes. Arch Pediatr Adolesc Med. 2002;156(6):533-539
33. Zemel BS, Kawchak DA, Fung EB, Ohene-Frempong K, Stallings VA. Effect of zinc supplementation on growth and body composition in children with sickle cell disease. Am J Clin Nutr. 2002;75(2):300-307
34. Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr. 1998;133(2):275-278
35. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2009;(4):CD003427
36. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia: prophylactic penicillin study II. J Pediatr. 1995;127(5):685-690
37. Berkovitch M, Papadouris D, Shaw D, Onuaha N, Dias C, Olivieri NF. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. Br J Clin Pharmacol. 1998;45(6):605-607
38. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333(11):699-703
39. Hsu LL, Batts BK, Rau JL. Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry. Respir Care. 2005;50(5):624-627
40. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The preoperative transfusion in sickle cell disease study group. N Engl J Med. 1995;333(4):206-213
41. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508
42. Waldron P, Pegelow C, Neumayr L, et al. Tonsillectomy, adenoidectomy, and myringotomy in sickle cell disease: perioperative morbidity: preoperative transfusion in sickle cell disease study group. J Pediatr Hematol Oncol. 1999;21(2):129-135
43. Vichinsky EP, Neumayr LD, Haberkern C, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. Am J Hematol. 1999;62(3): 129-138
44. Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the national preoperative transfusion study. Preoperative transfusion in sickle cell disease study group. Blood. 1997; 89(5):1533-1542
45. National Heart Lung and Blood Institute. Stroke prevention study in children with sickle cell anemia, iron overload stopped early [press release]. Available at: www.nih. gov/news/health/jun2010/nhlbi-03.htm. Accessed June 4, 2010
46. National Heart Lung and Blood Institute. NIH-funded study finds sickle cell treatment safe for young children [press release]. Available at: http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2788. Accessed May 12, 2011
47. Thornburg CD, Rogers ZR, Jeng MR, et al. Adherence to study medication and visits: fata from the BABY HUG trial. Pediatr Blood Cancer. 2010;54(2):260-264
48. Pavlakis SG, Rees RC, Huang X, et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the baby hug trial. Pediatr Blood Cancer. 2010;54(2):256-259
49. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr. 2010;156(1):66-70.e61
50. Martinez-Castaldi C, Silverstein M, Bauchner H. Child versus adult research: the gap in high-quality study design. Pediatrics. 2008;122(1):52-57
51. Cohen E, Goldman RD, Ragone A, et al. Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985-2005. Arch Pediatr Adolesc Med. 2010;164(3):283-288
52. Gil KM, Porter L, Ready J, Workman E, Sedway J, Anthony KK. Pain in children and adolescents with sickle cell disease: an analysis of daily pain diaries. Child Health Care. 2000;29(4):225-241
53. Bennett DR. Pain management for sickle cell disease in children and adults. Cochrane Database Syst Rev. 2009;(3):CD14003350
54. Benjamin LJ, Dampier CD, Jacox A, et al. Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. Glenview, IL: American Pain Society; 1999
55. Weitzman M. School absence rates as outcome measures in studies of children with chronic illness. J Chronic Dis. 1986;39(10):799-808
56. Fowler MG, Johnson MP, Atkinson SS. School achievement and absence in children with chronic health conditions. J Pediatr. 1985;106(4):683-687
57. Thies KM. Identifying the educational impli- cations of chronic illness in school children. J Sch Health. 1999;69(10):392-397
58. Griffin TC, McIntire D, Buchanan GR. Highdose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994; 330(11):733-737
59. Wilimas JA, Flynn PM, Harris S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med. 1994;329(7):472-476
60. Silliman C, Peterson VM, Mellman DL, Dixon DJ, Hambridge KM, Lane PA. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. J Lab Clin Med. 1993;122(1):48-54
61. Baum KF, MacFarlane DE, Maude GH, Serjeant GR. Topical antibiotics in chronic sickle cell leg ulcers. Trans R Soc Trop Med Hyg. 1987;81(5):847-849
62. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed). 1984;288(6430):1567-1570
63. Rabb LM, Grandison Y, Mason K, Hayes RJ, Serjeant B, Serjeant GR. A trial of folate supplementation in children with homozygous sickle cell disease. Br J Haematol. 1983;54(4):589-594
64. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20-26
65. Caldwell PHY, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364(9436):803- 811
66. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300-5311